|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
IL101728A
(en)
|
1991-05-03 |
2007-08-19 |
Univ Yale |
Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
|
|
US5786158A
(en)
|
1992-04-30 |
1998-07-28 |
Yale University |
Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
|
|
US20050112121A1
(en)
|
1992-04-30 |
2005-05-26 |
Yale University |
Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
|
|
US5840299A
(en)
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
EP0861261B9
(en)
|
1995-06-28 |
2010-02-24 |
Imperial Cancer Research Technology Limited |
Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
|
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
|
JPH09124697A
(ja)
|
1995-11-01 |
1997-05-13 |
Toagosei Co Ltd |
ペプチド及びモノクローナル抗体
|
|
DE69635899T2
(de)
|
1995-11-17 |
2006-11-23 |
Asahi Kasei Kabushiki Kaisha |
Polypeptid, das die differenzierung unterdrueckt
|
|
US20020137890A1
(en)
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US6121045A
(en)
|
1997-04-04 |
2000-09-19 |
Millennium Biotherapeutics, Inc. |
Human Delta3 nucleic acid molecules
|
|
US20030180784A1
(en)
|
1997-04-04 |
2003-09-25 |
Millennium Pharmaceuticals, Inc. |
Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
|
|
US20060122373A1
(en)
|
1997-04-04 |
2006-06-08 |
Millennium Pharmaceuticals, Inc. |
Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
|
|
EP0972041B2
(en)
|
1997-04-04 |
2017-01-18 |
Millennium Pharmaceuticals, Inc. |
Novel human delta3 compositions and therapeutic and diagnostic uses therefor
|
|
JP3957765B2
(ja)
|
1997-04-07 |
2007-08-15 |
ジェネンテク・インコーポレイテッド |
抗ｖｅｇｆ抗体
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
JP4171528B2
(ja)
|
1997-05-14 |
2008-10-22 |
旭化成株式会社 |
新規な分化抑制剤
|
|
AU8162898A
(en)
|
1997-06-18 |
1999-01-04 |
Trustees Of Columbia University In The City Of New York, The |
Angiogenic modulation by notch signal transduction
|
|
US6004528A
(en)
|
1997-09-18 |
1999-12-21 |
Bergstein; Ivan |
Methods of cancer diagnosis and therapy targeted against the cancer stemline
|
|
EP1100899A2
(en)
|
1998-07-27 |
2001-05-23 |
Amgen Inc. |
Delta-related polypeptides
|
|
EP1179541B1
(en)
|
1999-04-28 |
2004-06-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting VEGF
|
|
EP1672070A3
(en)
|
1999-12-01 |
2006-10-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20110131679A2
(en)
|
2000-04-19 |
2011-06-02 |
Thomas La Rosa |
Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
|
|
US20020028488A1
(en)
|
2000-06-19 |
2002-03-07 |
Sujay Singh |
Transgenic avian species for making human and chimeric antibodies
|
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
|
US6689744B2
(en)
|
2000-09-22 |
2004-02-10 |
Genentech, Inc. |
Notch receptor agonists and uses
|
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
|
WO2003011317A1
(en)
|
2001-07-25 |
2003-02-13 |
Lorantis Limited |
Modulators of notch signalling for use in immunotherapy
|
|
US7820178B2
(en)
|
2001-08-01 |
2010-10-26 |
University of Brisol |
VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
|
|
CA2465304A1
(en)
|
2001-11-14 |
2003-05-22 |
Lorantis Limited |
Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system
|
|
US20050137130A1
(en)
|
2001-11-14 |
2005-06-23 |
Bodmer Mark W. |
Medical treatment
|
|
WO2003042246A2
(en)
|
2001-11-14 |
2003-05-22 |
Lorantis Limited |
Inhibitors of the notch signalling pathway for use in the treatment of cancer
|
|
CA2469204A1
(en)
|
2001-12-07 |
2003-06-19 |
Regents Of The University Of Michigan |
Prospective identification and characterization of breast cancer stem cells
|
|
AUPS054702A0
(en)
*
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
GB0218879D0
(en)
|
2002-08-14 |
2002-09-25 |
Lorantis Ltd |
Medical treatment
|
|
JP2006515177A
(ja)
|
2002-09-10 |
2006-05-25 |
ロランティス リミテッド |
Ｎｏｔｃｈリガンドタンパク質を含む医薬組成物及び医学的処置
|
|
EP1631317A2
(en)
|
2003-06-06 |
2006-03-08 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20050079184A1
(en)
|
2003-08-08 |
2005-04-14 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
FR2859725B1
(fr)
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
|
EP1753442A2
(en)
|
2004-06-10 |
2007-02-21 |
Regeneron Pharmaceuticals, Inc. |
Method of administering and using vegf inhibitors for the treatment of human cancer
|
|
CA2567738C
(en)
|
2004-06-15 |
2010-12-21 |
F. Hoffmann-La Roche Ag |
The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
|
|
MXPA06014689A
(es)
|
2004-06-18 |
2008-03-11 |
Regeneron Pharma |
Inhibidores del vegf para el tratamiento de efusion pleural maligna.
|
|
EP1615036B1
(en)
|
2004-07-07 |
2007-09-19 |
F.Hoffmann-La Roche Ag |
Multimarker panel for diabetes type 1 and 2
|
|
EP1789446A2
(en)
|
2004-09-02 |
2007-05-30 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US20080254031A1
(en)
|
2004-09-09 |
2008-10-16 |
Exonhit Therapeutics Sa |
Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
|
|
US8911726B2
(en)
|
2004-09-22 |
2014-12-16 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human Igg4 antibodies
|
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
|
US20060134121A1
(en)
|
2004-10-29 |
2006-06-22 |
Gavin Thurston |
DII4 antagonists, assays, and therapeutic methods thereof
|
|
AU2005302846A1
(en)
|
2004-11-10 |
2006-05-18 |
Hubrecht Laboratorium |
Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
|
|
WO2006083355A2
(en)
|
2004-11-19 |
2006-08-10 |
Cornell Research Foundation, Inc. |
Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
|
|
US7432107B2
(en)
|
2005-01-24 |
2008-10-07 |
Roche Diagnostics Operations, Inc. |
Cardiac hormones for assessing cardiovascular risk
|
|
AU2006213856B2
(en)
|
2005-02-11 |
2011-03-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
RU2494107C2
(ru)
*
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP1885400A4
(en)
|
2005-06-02 |
2011-01-26 |
Galaxy Biotech Llc |
METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES
|
|
CN104356236B
(zh)
*
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
EP1917024A2
(en)
|
2005-08-12 |
2008-05-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating diseases with a vegf antagonist
|
|
US7906116B2
(en)
|
2005-09-01 |
2011-03-15 |
Parkash Gill |
Methods for using and identifying modulators of Delta-like 4
|
|
EP1928486A2
(en)
|
2005-09-01 |
2008-06-11 |
Vasgene Therapeutics, Inc. |
Methods for using and identifying modulators of delta-like 4
|
|
JP5129149B2
(ja)
|
2005-10-31 |
2013-01-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
癌を処置および診断するための組成物および方法
|
|
DK1962895T3
(da)
|
2005-12-16 |
2013-03-04 |
Regeneron Pharma |
TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
|
|
AU2007217100A1
(en)
|
2006-02-17 |
2007-08-30 |
Gilead Colorado, Inc. |
Antihypertensive therapy
|
|
WO2007103114A2
(en)
|
2006-03-07 |
2007-09-13 |
The Brigham & Women's Hospital, Inc. |
Notch inhibition in the treatment or prevention of atherosclerosis
|
|
US7354582B2
(en)
|
2006-03-10 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF antagonists for the treatment of malignant gliomas
|
|
US8871912B2
(en)
|
2006-03-24 |
2014-10-28 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
KR20090027227A
(ko)
*
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-ｄｌｌ4 항체 및 이의 사용 방법
|
|
KR20090016762A
(ko)
|
2006-06-06 |
2009-02-17 |
제넨테크, 인크. |
혈관 발달을 조정하기 위한 조성물 및 방법
|
|
US7919092B2
(en)
|
2006-06-13 |
2011-04-05 |
Oncomed Pharmaceuticals, Inc. |
Antibodies to notch receptors
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
ME00591A
(en)
|
2006-08-07 |
2011-12-20 |
|
Use of dii4 antagonists in ishemic injury or vascular insufficiency
|
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
|
UA110315C2
(uk)
*
|
2006-09-29 |
2015-12-25 |
Oncomed Pharm Inc |
Композиція та спосіб лікування раку
|
|
EA018260B1
(ru)
|
2006-09-29 |
2013-06-28 |
Онкомед Фармасьютикалз, Инк. |
Антитела к дельта-подобному лиганду 4 человека и их применение
|
|
WO2008133706A2
(en)
|
2006-10-20 |
2008-11-06 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
WO2008070350A2
(en)
|
2006-10-27 |
2008-06-12 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
|
WO2008070042A2
(en)
|
2006-12-04 |
2008-06-12 |
Medimmune, Inc. |
High potency recombinant antibodies, methods for producing them and use in cancer therapy
|
|
MX2009006202A
(es)
|
2006-12-11 |
2009-06-22 |
Genentech Inc |
Composiciones y metodos para el tratamiento de neoplasma.
|
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
|
TWI577695B
(zh)
|
2006-12-19 |
2017-04-11 |
建南德克公司 |
用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
|
|
AU2007338734A1
(en)
|
2006-12-20 |
2008-07-03 |
Vasgene Therapeutics, Inc. |
Methods for using and identifying modulators of delta-like 4
|
|
WO2008091222A1
(en)
|
2007-01-26 |
2008-07-31 |
Bioinvent International Ab |
Dll4 signaling inhibitors and uses thereof
|
|
RU2009144972A
(ru)
|
2007-05-04 |
2011-06-10 |
Айронвуд Фармасьютикалз, Инк. (Us) |
Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости
|
|
GB0709333D0
(en)
|
2007-05-15 |
2007-06-20 |
Smart Targeting Ltd |
Binding protein
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
CN101970486A
(zh)
|
2007-10-25 |
2011-02-09 |
布里斯托尔大学 |
特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
|
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-ｖｅｇｆ抗體
|
|
WO2009075565A1
(en)
|
2007-12-12 |
2009-06-18 |
Erasmus University Medical Center Rotterdam |
Methods for controlling vasculogenesis
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
AU2009235467A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Single variable domains against the Notch pathways
|
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
|
US20100260668A1
(en)
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CN104402998A
(zh)
*
|
2008-07-08 |
2015-03-11 |
昂考梅德药品有限公司 |
分离的抗体
|
|
JP5606438B2
(ja)
|
2008-07-23 |
2014-10-15 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗血管新生療法を受容可能な被験体の同定
|
|
EP2324358A1
(en)
|
2008-07-23 |
2011-05-25 |
F. Hoffmann-La Roche AG |
Monitoring anti-angiogenesis therapy
|
|
WO2010098788A2
(en)
*
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
RU2581962C2
(ru)
*
|
2008-09-19 |
2016-04-20 |
Медиммун Ллк |
Нацеленные средства связывания, направленные на dll4, и их применение
|
|
DK2356270T3
(da)
|
2008-11-07 |
2016-12-12 |
Fabrus Llc |
Kombinatoriske antistofbiblioteker og anvendelser deraf
|
|
NZ592151A
(en)
|
2008-12-12 |
2012-10-26 |
Boehringer Ingelheim Int |
Anti-igf antibodies
|
|
WO2010123891A1
(en)
|
2009-04-20 |
2010-10-28 |
Genentech, Inc. |
Adjuvant cancer therapy
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
|
|
CA2766166A1
(en)
|
2009-07-08 |
2011-01-13 |
Amgen Inc. |
Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
|
|
WO2011025964A2
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
KR20120060877A
(ko)
|
2009-09-01 |
2012-06-12 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
US20110172398A1
(en)
|
2009-10-02 |
2011-07-14 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules for anti-angiogenesis therapy
|
|
ES2700450T3
(es)
|
2009-10-16 |
2019-02-15 |
Oncomed Pharm Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
|
|
CA2778084A1
(en)
|
2009-10-23 |
2011-04-28 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using same
|
|
EP2493497A4
(en)
|
2009-11-01 |
2013-07-24 |
Brigham & Womens Hospital |
NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
|
|
CA2782299A1
(en)
|
2009-12-01 |
2011-06-09 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating cancers comprising k-ras mutations
|
|
MX2012008085A
(es)
*
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
|
JO3183B1
(ar)
|
2010-01-29 |
2018-03-08 |
Regeneron Pharma |
طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
|
|
US8551715B2
(en)
|
2010-02-12 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
|
SMT201700185T1
(it)
|
2010-08-23 |
2017-05-08 |
Univ Texas |
Anticorpi anti-ox40 e metodi di uso degli stessi
|
|
US8551479B2
(en)
*
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
WO2012068098A1
(en)
|
2010-11-15 |
2012-05-24 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating cancer with dll4 antagonists
|
|
JP5889800B2
(ja)
*
|
2010-12-01 |
2016-03-22 |
キッコーマン株式会社 |
大腸菌形質転換体、それを用いたフラビン結合型グルコースデヒドロゲナーゼの製造方法、および、変異型フラビン結合型グルコースデヒドロゲナーゼ
|
|
TWI530489B
(zh)
*
|
2011-03-22 |
2016-04-21 |
必治妥美雅史谷比公司 |
雙（氟烷基）－１，４－苯二氮呯酮化合物
|
|
AU2012271450A1
(en)
|
2011-06-17 |
2014-01-16 |
Adrian L. Harris |
Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies
|
|
LT3485903T
(lt)
*
|
2011-09-23 |
2023-02-27 |
Mereo Biopharma 5, Inc. |
Vegf/ dll4 surišantys agentai ir jų panaudojimas
|
|
EP2780354A4
(en)
*
|
2011-11-16 |
2015-06-24 |
Oncomed Pharm Inc |
HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
|
|
JP2015510397A
(ja)
|
2012-02-03 |
2015-04-09 |
メディミューン リミテッド |
抗体凝集物レベルを低下させるためのプロセスおよびそれによって産生される抗体
|
|
CN113967253A
(zh)
*
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
EP2849785A4
(en)
*
|
2012-05-16 |
2015-12-16 |
Oncomed Pharm Inc |
METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
JP2015520172A
(ja)
|
2012-05-31 |
2015-07-16 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｄｌｌ−４に結合する抗原結合蛋白質
|
|
KR101535341B1
(ko)
|
2012-07-02 |
2015-07-13 |
한화케미칼 주식회사 |
Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
|
|
LT3495387T
(lt)
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
CN104661679A
(zh)
|
2012-09-28 |
2015-05-27 |
勃林格殷格翰国际有限公司 |
包含双重血管生成素-2/Dll4结合物和抗VEGF药剂的药物组合
|
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
US9599620B2
(en)
|
2012-10-31 |
2017-03-21 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
|
KR20180008921A
(ko)
|
2012-11-01 |
2018-01-24 |
애브비 인코포레이티드 |
항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
WO2015130751A1
(en)
|
2014-02-26 |
2015-09-03 |
Medimmune, Llc |
Methods of treatment with dll4 antagonists
|
|
AU2015229591B2
(en)
*
|
2014-03-11 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-EGFRvlll antibodies and uses thereof
|
|
CA2952315A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
|
WO2016070051A2
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
EP3353204B1
(en)
*
|
2015-09-23 |
2023-10-18 |
Mereo BioPharma 5, Inc. |
Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
|
|
WO2020012447A1
(en)
|
2018-07-13 |
2020-01-16 |
Composite Interceptive Med-Science Laboratories Private Limited |
Polyherbal formulation and method for production thereof
|